evenfolio

Chemicals · NSE: NEOGEN

Neogen Chemicals

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
2,672.30−4.86%

Q2 FY27 earnings call · Guided by management

Call held 2 Nov 2026 · Read the filing on NSEFiling

₹150–200​CrAdditional revenue potential · OrganolithiumKanani · p. 3
₹1,300–1,500​CrNet debt · FY28Sarathy · Q&A · p. 7
₹250–300​CrBattery chemicals revenue · Battery chemicals · current yearKanani · Q&A · p. 9
80–90​%Salt capacity utilisation · Electrolyte salts · next yearKanani · Q&A · p. 9
M.Cap
₹8,028Cr
P/E
198.6×
1Y return
+119.54%
From 52W high
−7.0%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue296209+41.8%250+18.2%
EBITDA4530+51.3%48-6.0%
EBITDA margin15.3%14.4%+96 bps19.3%-395 bps
PBTProfit before tax135+151.4%23-44.9%
Net profit83+144.2%17-51.9%
EPS (₹)2.961.28+131.3%6.29-52.9%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures. In Q1 FY27 the filing tags the owners' profit as ₹0 Cr against its own period profit; the period profit less minority interest is shown.

Guidance

Revenue · FY27Rs 1,350-1,400 CrkeptConsolidated FY27 revenue expected around INR 1,350-1,400 crore
Revenue · Organolithium · long termRs 150-200 CrOrganolithium expansion expected to add INR 150-200 crore revenue potential
Revenue · Organolithium · FY28Rs 50-75 CrNew Organolithium capacity to add INR 50-75 crore next year, INR 150-200 crore the year after
Revenue · Battery chemicals · FY27Rs 250-300 CrBattery chemicals FY27 revenue expected at INR 250-300 crore
Revenue · Battery chemicals · FY28Rs 1,000 CrBattery chemicals FY28 revenue expected above INR 1,000 crore
Revenue · Electrolyte salts · FY28Rs 1,000 CrSalt revenue close to INR 1,000 crore for next year
Revenue · Base business · FY27Rs 50-100 CrBase business FY27 seen INR 50-100 crore above earlier INR 950-1,050 crore guidance
Revenue · Base business · FY28Rs 1,200 CrReason given: new Organolithium capacity not in earlier plan
Revenue · Battery chemicals · FY29Rs 2,500-3,000 CrBattery business revenue INR 2,500-3,000 crore and INR 500 crore plus EBITDA at full use by FY29
EBITDA · FY29Rs 500-600 CrEBITDA of INR 500-600 crore expected by FY29, enough to fund capex internally
EBITDA margin · Neogen Chemicals18-20%Neogen Chemicals (standalone) EBITDA margin guidance kept at 18% to 20%
Utilisation · Electrolyte salts · FY2880-90%Salt capacity utilisation of about 80-90% next year, mostly sold externally
Capex · OrganolithiumRs 45 CrOrganolithium capacity at Patancheru to double to 600 MTPA for up to INR 45 crore
Capex · Battery chemicalsRs 1,800-2,000 CrBattery investment of about INR 1,800-2,000 crore targeted at 20%+ return on capital

Battery chemicals: Earlier FY27 battery split: INR 200 crore from salt, INR 100 crore from electrolyte

Harin Kanani · Managing Director · Q&A · p. 8
“If you remember in the last call, we had given a breakdown that INR 200 crore, we are expecting from the salt business and INR 100 crore from electrolyte.”

Electrolyte salts: Salt utilisation of 70-80% targeted next year

Harin Kanani · Managing Director · Q&A · p. 21
“so that in the salt we can achieve 70%/80% utilisation levels by next year.”

Consolidated annual guidance on track

Harin Kanani · Managing Director · p. 5
“we remain fully on track to meet our consolidated annual guidance”

Battery chemicals: 30,000 tonne capacity expected fully utilised by FY29; more capex to plan in FY29

Harin Kanani · Managing Director · Q&A · p. 11
“therefore, by FY29, we feel there is a very strong possibility that our 30,000 metric tonne gets fully utilised. And hopefully, by FY30, we should be falling short of capacity, for which we have to plan some more capex in FY29.”

Electrolyte salts: Full salt capacity expected to be used for US market next year

Harin Kanani · Managing Director · Q&A · p. 14
“And we are confident that our next year full capacity should get fully utilised for the U.S. market because one, we have a non-FEOC or basically 45x compliant supply as well as we have Morita’s stable technology.”

More figures from the call

Electrolyte salts · Guidance
₹800–1,000​CrSalt revenue
“But if we were to just say, almost 80% of 5,500 tonne is consumed and sold internationally, then with today's prices, we should be somewhere around INR 800 crore to INR 1,000 crore of revenue already.”
Harin Kanani · Managing Director · Q&Ap. 10
Base business · Guidance
₹1,100​CrBase business revenue · this year
“And this year should be INR 1,100 crore plus kind of revenue, is what I am expecting.”
Harin Kanani · Managing Director · Q&Ap. 11

In short

  1. 01Consolidated FY27 revenue expected around INR 1,350-1,400 crore, in line with or slightly above earlier guidance.
  2. 02Battery chemicals revenue guided at INR 250-300 crore for FY27 and over INR 1,000 crore for FY28.
  3. 03Base business FY27 revenue expected at INR 1,100 crore plus; FY28 around INR 1,200 crore.
  4. 04Organolithium capacity to double to 600 MTPA for up to INR 45 crore, adding INR 150-200 crore revenue potential.
  5. 05Maiden QIP raised INR 600 crore, mainly to deleverage; FY28 net debt expected at INR 1,300-1,500 crore.
  6. 06Insurance claims received and receivable total INR 316 crore; rebuilt Dahej plant in trial runs.
  7. 07Standalone EBITDA margin guidance kept at 18% to 20%.

Capex

Battery chemicals: New salt or electrolyte plant takes 15-18 months in existing setup

Harin Kanani · Managing Director · Q&A · p. 18
“So ideally, I would say, 15 months to 18 months is a good time for salt or electrolyte plant.”

Battery chemicals: Next 30,000-tonne round would cost 60-70% of a new first plant

Harin Kanani · Managing Director · Q&A · p. 23
“we would be basically doing incremental capex, which is 60% - 70% as compared to somebody setting up a first 30,000 tonne plant.”

Organolithium: Organolithium expansion targeted for completion by next September (H1)

Harin Kanani · Managing Director · Q&A · p. 6
“We expect the Organolithium additional capacity to be targetted to be completed by next September by H1.”

Rebuilt Dahej plant in trial runs; commercial production expected this financial year

Harin Kanani · Managing Director · p. 4
“the trial runs of the rebuilt Dahej plant are currently underway, and we expect to commence commercial production shortly within this current financial year so that next quarter, we will be able to fully utilise these facilities.”

Battery chemicals: Electrolyte and salt projects on track; electrolyte trial runs begun

Harin Kanani · Managing Director · p. 5
“Our project mechanical completion timelines remain on track for both, electrolyte and electrolyte salts. For electrolytes, mechanical assembly is complete and trial runs have begun alongside facility validation and active joint trials of recipes with multiple Giga factories.”

Capacity

Organolithium: Organolithium plant running near 25 tonnes per month, fully utilised

Harin Kanani · Managing Director · Q&A · p. 18
“So we are on track and very close to the 25 tonnes per month kind of utilisation or above. So we are fully utilising the facility.”

Electrolyte salts: Minimum salt plant size is 3,000-5,000 tonnes for liquid salt

Harin Kanani · Managing Director · Q&A · p. 18
“The minimum size for the salt capacity is between 3,000 tonnes to 5,000 tonnes for liquid salt.”

Battery chemicals: Capacity may need to rise 8-9 times over next 7-8 years

Harin Kanani · Managing Director · Q&A · p. 19
“in the next 7 or 8 years, we have to increase capacity 8 to 9 times of what we have today.”

Organolithium: Organolithium running at 300 tonnes run rate; may go higher by end of year

Harin Kanani · Managing Director · Q&A · p. 7
“And currently, the increased capacity is running at 300 tonnes kind of a run rate. So, we would be doing 300 tonnes and may be if we are able to do some incremental increase in capacity even higher by end of this year.”

Battery chemicals: Illustration: 30% share would need 300 KT electrolyte, 380 KT salt, about 10x today

Harin Kanani · Managing Director · p. 19
“Let us say, Neogen also has a 30% kind of market share - based on just looking at the China model, no other logic. That also requires a 300 KT kind of electrolyte capacity and 380 KT salt capacity - approximately 10 times of what we have today.”

Order book

Battery chemicals: Purchase orders in hand point to Q3 battery revenue above Q2

Harin Kanani · Managing Director · Q&A · p. 8
“Already, we have received good POs in hand where we can see that our Q3 should be even better than Q2.”

Segments

Battery chemicals: Battery chemicals Q2 FY27 revenue INR 37 crore vs INR 5 crore a year ago

Harin Kanani · Managing Director · p. 3
“with Q2 FY27 revenue reaching INR 37 crore compared to INR 5 crore in the same quarter in FY26.”

Neogen Ionics: Neogen Ionics revenue stated at INR 27 crore vs INR 5 crore last year

Gopikrishnan Sarathy · Chief Financial Officer · p. 5
“Revenues at Neogen Ionics was at INR 27 crore versus INR 5 crore last year.”

Battery chemicals: Battery chemicals expected to scale up substantially in Q3 and Q4 FY27

Harin Kanani · Managing Director · p. 3
“we expect substantial scale up in Q3 & Q4 FY27 and beyond, supported by the upcoming ACC battery manufacturing ecosystem built in India”

Battery chemicals: Even stronger Q4 expected for battery chemicals

Harin Kanani · Managing Director · Q&A · p. 8
“So, we are expecting even a stronger Q4. So, you can keep seeing significant increases as we go from Q1 to Q2, Q3 to Q4.”

Battery chemicals: Battery revenue so far is mostly salt; electrolyte under 5-10%

Harin Kanani · Managing Director · Q&A · p. 11
“Most of it is salt. I mean, electrolyte is less than 5%/10% of that.”

Demand

Battery chemicals: Salt approvals from five international customers; supply started to two

Harin Kanani · Managing Director · p. 5
“for lithium electrolytes salts, we have secured provisional approvals at our Dahej facility from five major international customers, completed final site audits for three US based manufacturers and already commenced commercial supply with two international customers.”

Battery chemicals: Dahej approved by three of five salt customers; fourth expected soon

Harin Kanani · Managing Director · Q&A · p. 8
“Like our Dahej facility, as we mentioned, is already approved by three out of five. The fourth one also we are expecting quite soon.”

Electrolyte salts: About 500-1,000 tonnes of salt could be consumed locally, depending on customers

Harin Kanani · Managing Director · Q&A · p. 10
“somewhere between 500 to 1,000 tonnes, is what can get consumed locally. Of course, this depends on the customer choice.”

Organolithium: Organolithium approvals received in semiconductor materials and specialty polymers

Harin Kanani · Managing Director · Q&A · p. 7
“We have already got approvals in both, semiconductor materials as well as for the specialty polymers where also there is a strong volume demand.”

About 60 GWh of Indian cell capacity expected by end FY27 or early FY28

Harin Kanani · Managing Director · Q&A · p. 9
“My guess is that total gigawatt hour capacity - which is coming online by the end of this financial year/early next financial year - is 60 giga.”

Margins and costs

Electrolyte salts: Lithium is pass-through; quarterly price reset with long-term customers

Harin Kanani · Managing Director · Q&A · p. 19
“Lithium is completely pass-through. And currently, what we have is a quarterly reset with our long-term customers”

Consolidated EBITDA hit by Neogen Ionics fixed costs and Dahej rebuild expenses

Gopikrishnan Sarathy · Chief Financial Officer · p. 6
“Consolidated EBITDA reflected the initial fixed cost absorption at Neogen Ionics, as the capacity is yet to ramp up alongside the temporary expenses related to the Dahej rebuild, interim tolling arrangement and elevated input costs.”

Electrolyte: Electrolyte pricing models agreed with customers despite no long-term contracts

Harin Kanani · Managing Director · Q&A · p. 21
“We have had pricing models, which have been agreed upon that this is how we would do the pricing and that is accepted by the customer.”

Electrolyte salts: New salt customers offered monthly reset or fixed 3-9 month price with advances

Harin Kanani · Managing Director · Q&A · p. 20
“So a back-to-back lithium coverage and a fixed price for 3 months, 6 months, 9 months period with advances kind of a situation or a monthly reset is what we are talking to new customers.”

Neogen Chemicals: Base Neogen Chemicals business at 18%+ EBITDA level

Harin Kanani · Managing Director · Q&A · p. 23
“On the base Neogen Chemicals business, we are at 18%+ kind of EBITDA level.”

Debt and working capital

INR 200 crore of bonds to be repaid

Harin Kanani · Managing Director · Q&A · p. 13
“So we have already faster resolution to repay INR 200 crore of bond.”

CRISIL revised long-term outlook to A- stable from negative; short-term A2+ reaffirmed

Harin Kanani · Managing Director · p. 4
“CRISIL rating has revised the outlook of Neogen's long-term bank facility to CRISIL A- stable from negative while reaffirming the short-term rating at CRISIL A2+.”

INR 465 crore in liquid investments; consolidated net debt INR 1,095 crore at Sept 30, 2026

Gopikrishnan Sarathy · Chief Financial Officer · p. 6
“As on September 30, 2026, we maintained a strong liquidity profile of INR 465 crore in liquid investment in fixed deposits. It brings our consolidated net debt to INR 1,095 crore while standalone net debt stood at INR 378 crore.”

Interest costs expected to trend down

Gopikrishnan Sarathy · Chief Financial Officer · p. 6
“Interest costs are expected to trend downwards moving ahead, supported by term debt reduction using the QIP proceeds, lower borrowing costs following our credit rating upgrade and incoming insurance claim disbursement.”

Inventory up as Dahej not fully online and tolling continues

Harin Kanani · Managing Director · Q&A · p. 12
“This is a situation where our Dahej plant is coming online. At the same time, it is not fully come online. So we still have to continue with our outsourcing or toll manufacturing arrangement.”

Fund raising

Maiden QIP raised INR 600 crore, oversubscribed 6.5x

Harin Kanani · Managing Director · p. 4
“completion of our maiden Qualified Institutional Placement (QIP) raising INR 600 crore. Demonstrating strong institutional faith in our business, the QIP was oversubscribed 6.5x with broad-based participation from leading global and domestic investors.”

QIP proceeds being used to deleverage the balance sheet

Harin Kanani · Managing Director · p. 4
“We are deploying these proceeds strategically to deleverage our balance sheet as we prepare to fund our next phase of growth in the future.”

QIP proceeds for long-term loan repayment, working capital and general corporate purposes

Harin Kanani · Managing Director · Q&A · p. 16
“And QIP proceeds would be used the way we have originally said - for repayment of long-term loan, for some working capital dependency reduction, and the third would be for general corporate purposes.”

Morita second instalment expected by end of Q3 or early Q4

Harin Kanani · Managing Director · Q&A · p. 7
“And of course, you will also have Morita second instalment by the end of Q3 or early Q4.”

Future capex expected to be funded internally

Harin Kanani · Managing Director · Q&A · p. 19
“With those kind of numbers, you know, we should be able to fund it internally.”

Acquisitions and new business

Battery chemicals: Neogen Ionics to take over electrolyte salt business from NML for INR 245 crore

Harin Kanani · Managing Director · p. 5
“Neogen Ionics Limited has executed a business transfer agreement to consolidate the lithium-ion electrolyte salt (including LiPF6), undertaking under our step-down subsidiary Neogen Morita New Materials Limited (NML) for a cash consideration of INR 245 crore on a going concern basis”

One-offs

Insurance claims received and receivable total INR 316 crore

Harin Kanani · Managing Director · p. 4
“With this, our total on account claims received and receivable now stands at INR 316 crore inclusive of accepted claims and scrap sales to date.”

Insurance recoveries to date INR 164 crore, incl. INR 155 crore on account and INR 9 crore salvage

Harin Kanani · Managing Director · p. 4
“cumulative recoveries to date stands at INR 164 crore, comprising INR 155 crore on account payment (including a recent tranche of INR 15 crore received in July 2026) and INR 9 crore from salvage realisation.”

Additional insurance claim of INR 152 crore accepted on October 29, 2026

Harin Kanani · Managing Director · p. 4
“Further, on October 29, 2026, the company accepted an additional claim amount of INR 152 crore from the insurance, which will be released in due course.”

Insurance claim expected to be received in Q3

Harin Kanani · Managing Director · Q&A · p. 7
“So, in the next few weeks, we are expecting (the insurance claim). So that will come in Q3.”

Risks

Margin volatility expected this year and next

Harin Kanani · Managing Director · Q&A · p. 24
“I know in the beginning this year and next year, the margins, there will be some volatility.”

Quarter faced Middle East conflicts, supply friction, feedstock inflation, Dahej overheads

Harin Kanani · Managing Director · p. 3
“this performance came on the back of a complex macro environment marked by Middle East geopolitical conflicts, supply chain friction, feedstock cost inflation and temporary overheads from our Dahej facility rebuild.”

Electrolyte salts: Chinese-owned US salt plants seen as posturing; few customers likely interested

Harin Kanani · Managing Director · Q&A · p. 16
“So I think it is more posturing and more hope of a policy change, but the way things stand today, very few customers would be interested in a facility which is owned by Chinese or controlled by Chinese in the U.S.”

Ramp-up of Indian cell production named as the item to watch

Harin Kanani · Managing Director · Q&A · p. 21
“Only the ramp-up of cell production is what we need to watch carefully.”

Electrolyte salts: Long-term salt contracts have no take-or-pay clause

Harin Kanani · Managing Director · Q&A · p. 21
“Of course, the long-term contract does not have a ‘take or pay’.”

Other

Q2 FY27 consolidated revenue grew 42% to INR 296 crore

Gopikrishnan Sarathy · Chief Financial Officer · p. 5
“Revenue grew by 42% to INR 296 crore fuelled by consistent volume expansion across core segments.”

Consolidated EBITDA up 51% to INR 45 crore; standalone EBITDA INR 54 crore at 18.6% margin

Gopikrishnan Sarathy · Chief Financial Officer · p. 6
“Consolidated EBITDA grew by 51% to INR 45 crore, while standalone EBITDA delivered strong 54% growth to INR 54 crore with a margin of 18.6%.”

Consolidated PAT up 144% to INR 8 crore; standalone PAT up 127% to INR 21 crore

Gopikrishnan Sarathy · Chief Financial Officer · p. 6
“Consolidated PAT grew 144% to INR 8 crore, while standalone PAT surged 127% to INR 21 crore.”

About INR 18-20 crore of material bought by parent and transferred to Neogen Ionics

Harin Kanani · Managing Director · Q&A · p. 12
“about INR 18/20 crore worth of material is basically bought by Neogen Chemicals and transferred to Neogen Ionics.”

Electrolyte: Moving approved electrolyte customers from Dahej to Pakhajan to take 2-3 months

Harin Kanani · Managing Director · Q&A · p. 17
“it will be kind of a transfer from Dahej to Pakhajan and that will be relatively shorter - 2 to 3 months.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools